CD19 and cancer: For example, NK-92 cells engineered to express different CARs targeting CD19, CD20, CD38, HER2, PSMA or GD2 were considered as allogeneic “off-the-shelf” immunotherapeutic products and held great promise for the development of effective anti-cancer treatments [114, 144, 167, 168].